The CCDC9 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population for functional study of the human CCDC9 gene. This heterogeneous pool of near-haploid HAP1 cells carries targeted disruptions in the endogenous CCDC9 locus, resulting in loss of the coiled-coil domain-containing protein 9. The polyclonal format avoids clonal artifacts and provides a robust model for investigating gene function. The CRISPR-mediated disruption does not introduce selectable markers, preserving native cellular context for downstream assays. This model is ideal for exploring CCDC9 roles in protein scaffolding and signaling.
The HAP1 cell line is a near-haploid human fibroblast-like cell derived from the KBM-7 chronic myeloid leukemia lineage. Originating from a male donor, HAP1 cells maintain wild-type TP53 and a predominantly haploid karyotype, simplifying genetic analysis and enabling unambiguous genotype-phenotype correlations. The haploid state ensures knockout of a single allele abolishes protein expression, making it a powerful platform for loss-of-function studies. These cells exhibit robust growth and are amenable to standard culture and transfection protocols, facilitating their use in imaging and high-throughput assays.
CCDC9 encodes a coiled-coil domain-containing protein, a motif known to mediate protein-protein interactions and complex assembly. Although its interactors are not fully defined, coiled-coil domains often facilitate dimerization or scaffolding, suggesting CCDC9 may organize macromolecular complexes at the interface of cytoskeletal and signaling networks. Potential binding partners could include adaptor proteins, kinases, or structural elements, positioning CCDC9 as a key node in cellular organization. Knockout studies with this model can reveal its functional contributions to processes such as cell adhesion, polarity, and signal transduction.
The near-haploid HAP1 background enhances the value of the CCDC9 knockout model by eliminating compensatory wild-type alleles, ensuring complete loss of function. This genetic clarity improves the reliability of quantitative phenotypic assays. The chronic myeloid leukemia origin of HAP1 also provides a cancer-relevant context for probing potential tumor-related functions of CCDC9. The polyclonal nature further strengthens statistical robustness in experiments, enabling confident identification of CCDC9-dependent phenotypes in cell proliferation, migration, and morphology.
Typical applications include verification of CCDC9 disruption via Western blotting and RT-qPCR, localization studies by immunofluorescence, and functional assays such as cell proliferation, colony formation, and migration. The polyclonal pool is suitable for both short-term and longitudinal studies, supporting investigation of dynamic cellular processes. When paired with appropriate controls, these cells can be integrated into drug or genetic screens to identify modifiers of CCDC9-mediated pathways. For technical support, please contact Ascent Research.
